ZhaLF HM J, et al. Protective effects of PCSK9 inhibitors on renal function in ASCVD patients at high risk for contrast-associated acute kidney injury. Angiology. 2025.
2.
BillingsFTHendricksPASchildcroutJS, et al. High-dose perioperative atorvastatin and acute kidney injury following cardiac surgery: a randomized clinical trial. JAMA. 2016;315:877-888.
3.
DingZPothineniNVKGoelALüscherTFMehtaJL.PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. Cardiovasc Res. 2020;116:908-915.
4.
ZhangZShaoXJiangN, et al. Caspase-11-mediated tubular epithelial pyroptosis underlies contrast-induced acute kidney injury. Cell Death Dis. 2018;9:983.
5.
Bernelot MoensSJNeeleAEKroonJ, et al. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolemia. Eur Heart J. 2017;38:1584-1593.
6.
WalleyKRThainKRRussellJA, et al. PCSK9 is a critical regulator of innate immune response and septic shock outcome. Sci Transl Med. 2014;6:258ra143.
